10,640 Shares in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Acquired by Oxford Wealth Group LLC

Oxford Wealth Group LLC acquired a new stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the first quarter, HoldingsChannel.com reports. The fund acquired 10,640 shares of the company’s stock, valued at approximately $106,000.

Other hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in Recursion Pharmaceuticals by 2.2% in the 1st quarter. Vanguard Group Inc. now owns 16,014,764 shares of the company’s stock valued at $159,667,000 after acquiring an additional 349,554 shares during the last quarter. Mubadala Investment Co PJSC bought a new stake in shares of Recursion Pharmaceuticals in the fourth quarter worth about $128,041,000. Sumitomo Mitsui Trust Holdings Inc. lifted its position in shares of Recursion Pharmaceuticals by 12.6% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 10,362,803 shares of the company’s stock worth $103,317,000 after buying an additional 1,159,023 shares in the last quarter. Nikko Asset Management Americas Inc. boosted its stake in Recursion Pharmaceuticals by 12.6% during the first quarter. Nikko Asset Management Americas Inc. now owns 10,362,803 shares of the company’s stock valued at $103,110,000 after buying an additional 1,159,023 shares during the last quarter. Finally, Norges Bank purchased a new position in Recursion Pharmaceuticals during the 4th quarter valued at approximately $34,825,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Insider Transactions at Recursion Pharmaceuticals

In related news, COO Tina Marriott sold 6,000 shares of the company’s stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $8.13, for a total transaction of $48,780.00. Following the transaction, the chief operating officer now directly owns 535,457 shares in the company, valued at approximately $4,353,265.41. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, COO Tina Marriott sold 6,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $8.13, for a total transaction of $48,780.00. Following the completion of the sale, the chief operating officer now directly owns 535,457 shares of the company’s stock, valued at approximately $4,353,265.41. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $9.17, for a total value of $104,968.99. Following the completion of the transaction, the director now directly owns 7,186,913 shares in the company, valued at approximately $65,903,992.21. The disclosure for this sale can be found here. In the last quarter, insiders sold 252,235 shares of company stock worth $2,040,900. 15.75% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

RXRX has been the topic of several recent research reports. KeyCorp decreased their price objective on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Needham & Company LLC reiterated a “buy” rating and set a $17.00 price objective on shares of Recursion Pharmaceuticals in a research report on Tuesday, June 25th.

Recursion Pharmaceuticals Stock Performance

RXRX stock traded down $0.24 during midday trading on Tuesday, reaching $7.95. 2,397,268 shares of the company traded hands, compared to its average volume of 6,044,628. The firm has a market capitalization of $1.89 billion, a price-to-earnings ratio of -4.97 and a beta of 0.83. The business has a 50 day moving average of $8.44 and a 200-day moving average of $9.51. Recursion Pharmaceuticals, Inc. has a 52-week low of $4.97 and a 52-week high of $15.74.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.04. Recursion Pharmaceuticals had a negative return on equity of 79.96% and a negative net margin of 765.90%. The company had revenue of $13.80 million during the quarter, compared to the consensus estimate of $11.10 million. During the same period last year, the company earned ($0.34) earnings per share. Recursion Pharmaceuticals’s revenue was up 14.0% on a year-over-year basis. Research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.56 earnings per share for the current year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.